Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Aug;68(2):393–398. doi: 10.1038/bjc.1993.347

Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.

D C Johannessen 1, H Adlercreutz 1, T Fotsis 1, P E Lønning 1
PMCID: PMC1968556  PMID: 8135918

Abstract

Plasma and urinary oestrogens were measured in nine breast cancer patients (eight postmenopausal women and one man) before and during treatment with the aromatase inhibitor 4-hydroxyandrostenedione. Urinary oestrogens were measured by using a highly specific GC-MS method. Plasma levels of oestrone, oestradiol and oestrone sulphate were suppressed by 66.6% (+/- 3.6%), 57.7% (+/- 5.1%) and 51.8% (+/- 6.4%) respectively (P < 0.005 for all). Twenty-four hour urinary excretion of total oestrogens, oestradiol, oestriol, 2-hydroxyoestrone, 16 alpha-hydroxyoestrone and the minor metabolites 16 beta- and 15 alpha-hydroxyoestrone were all suppressed by mean values ranging from 60% to 82%, (oestradiol: P < 0.025, otherwise P < 0.005). There were no significant changes in the ratios between the different plasma oestrogens. The finding of sustained plasma and urinary oestrogens at 20-40% compared to their control levels indirectly support a hypothesis of alternative oestrogen sources in postmenopausal breast cancer patients on treatment with 4-hydroxyandrostenedione.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beardwell C. G., Hindley A. C., Wilkinson P. M., Todd I. D., Ribeiro G. G., Bu'Lock D. Trilostane in the treatment of advanced breast cancer. Cancer Chemother Pharmacol. 1983;10(3):158–160. doi: 10.1007/BF00255752. [DOI] [PubMed] [Google Scholar]
  2. Bolt H. M. Metabolism of estrogens--natural and synthetic. Pharmacol Ther. 1979;4(1):155–181. doi: 10.1016/0163-7258(79)90018-4. [DOI] [PubMed] [Google Scholar]
  3. Brodie A. M., Brodie H. J., Romanoff L., Williams J. G., Williams K. I., Wu J. T. Inhibition of estrogen biosynthesis and regression of mammary tumors by aromatase inhibitors. Adv Exp Med Biol. 1981;138:179–190. doi: 10.1007/978-1-4615-7192-6_11. [DOI] [PubMed] [Google Scholar]
  4. Brodie A. M., Garrett W. M., Hendrickson J. R., Tsai-Morris C. H., Marcotte P. A., Robinson C. H. Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids. 1981 Dec;38(6):693–702. doi: 10.1016/0039-128x(81)90087-8. [DOI] [PubMed] [Google Scholar]
  5. Brodie A. M., Schwarzel W. C., Shaikh A. A., Brodie H. J. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology. 1977 Jun;100(6):1684–1695. doi: 10.1210/endo-100-6-1684. [DOI] [PubMed] [Google Scholar]
  6. Conney A. H. Induction of microsomal cytochrome P-450 enzymes: the first Bernard B. Brodie lecture at Pennsylvania State University. Life Sci. 1986 Dec 29;39(26):2493–2518. doi: 10.1016/0024-3205(86)90103-7. [DOI] [PubMed] [Google Scholar]
  7. Coombes R. C., Goss P., Dowsett M., Gazet J. C., Brodie A. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet. 1984 Dec 1;2(8414):1237–1239. doi: 10.1016/s0140-6736(84)92795-8. [DOI] [PubMed] [Google Scholar]
  8. Coombes R. C., Powles T. J., Muindi J., Hunt J., Ward M., Perez D., Neville A. M. Trilostane therapy for advanced breast cancer. Cancer Treat Rep. 1985 Apr;69(4):351–354. [PubMed] [Google Scholar]
  9. Dowsett M., Cunningham D. C., Stein R. C., Evans S., Dehennin L., Hedley A., Coombes R. C. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res. 1989 Mar 1;49(5):1306–1312. [PubMed] [Google Scholar]
  10. Dowsett M., Goss P. E., Powles T. J., Hutchinson G., Brodie A. M., Jeffcoate S. L., Coombes R. C. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 1987 Apr 1;47(7):1957–1961. [PubMed] [Google Scholar]
  11. Dowsett M., Harris A. L., Stuart-Harris R., Hill M., Cantwell B. M., Smith I. E., Jeffcoate S. L. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients. Br J Cancer. 1985 Oct;52(4):525–529. doi: 10.1038/bjc.1985.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dowsett M., Santner S. J., Santen R. J., Jeffcoate S. L., Smith I. E. Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients. Br J Cancer. 1985 Jul;52(1):31–35. doi: 10.1038/bjc.1985.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Dowsett M., Stein R. C., Mehta A., Coombes R. C. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol (Oxf) 1990 May;32(5):623–634. doi: 10.1111/j.1365-2265.1990.tb00906.x. [DOI] [PubMed] [Google Scholar]
  14. Fishman J., Hellman L., Zumoff B., Cassouto J. Pathway and stereochemistry of the formation of estriols in man. Biochemistry. 1966 Jun;5(6):1789–1794. doi: 10.1021/bi00870a003. [DOI] [PubMed] [Google Scholar]
  15. Fotsis T., Adlercreutz H. The multicomponent analysis of estrogens in urine by ion exchange chromatography and GC-MS--I. Quantitation of estrogens after initial hydrolysis of conjugates. J Steroid Biochem. 1987 Aug;28(2):203–213. doi: 10.1016/0022-4731(87)90379-7. [DOI] [PubMed] [Google Scholar]
  16. Grodin J. M., Siiteri P. K., MacDonald P. C. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab. 1973 Feb;36(2):207–214. doi: 10.1210/jcem-36-2-207. [DOI] [PubMed] [Google Scholar]
  17. Harris A. L., Cantwell B. M., Dowsett M. High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer. Br J Cancer. 1988 Oct;58(4):493–496. doi: 10.1038/bjc.1988.247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Harris A. L., Dowsett M., Smith I. E., Jeffcoate S. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. Eur J Cancer Clin Oncol. 1984 Apr;20(4):463–469. doi: 10.1016/0277-5379(84)90230-x. [DOI] [PubMed] [Google Scholar]
  19. Jacobs S., Lønning P. E., Haynes B., Griggs L., Dowsett M. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J Enzyme Inhib. 1991;4(4):315–325. doi: 10.3109/14756369109030396. [DOI] [PubMed] [Google Scholar]
  20. Jones A. L., MacNeill F., Jacobs S., Lonning P. E., Dowsett M., Powles T. J. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer. 1992;28A(10):1712–1716. doi: 10.1016/0959-8049(92)90074-c. [DOI] [PubMed] [Google Scholar]
  21. Larner J. M., Shackleton C. H., Roitman E., Schwartz P. E., Hochberg R. B. Measurement of estradiol-17-fatty acid esters in human tissues. J Clin Endocrinol Metab. 1992 Jul;75(1):195–200. doi: 10.1210/jcem.75.1.1619010. [DOI] [PubMed] [Google Scholar]
  22. Longcope C. The metabolism of estrone sulfate in normal males. J Clin Endocrinol Metab. 1972 Jan;34(1):113–122. doi: 10.1210/jcem-34-1-113. [DOI] [PubMed] [Google Scholar]
  23. Lønning P. E., Dowsett M., Powles T. J. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem. 1990 Mar;35(3-4):355–366. doi: 10.1016/0022-4731(90)90241-j. [DOI] [PubMed] [Google Scholar]
  24. Lønning P. E., Jacobs S., Jones A., Haynes B., Powles T., Dowsett M. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer. 1991 May;63(5):789–793. doi: 10.1038/bjc.1991.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lønning P. E., Johannessen D. C., Thorsen T. Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. Br J Cancer. 1989 Jul;60(1):107–111. doi: 10.1038/bjc.1989.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lønning P. E., Johannessen D. C., Thorsen T., Ekse D. Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition. J Steroid Biochem. 1989 Oct;33(4A):541–545. doi: 10.1016/0022-4731(89)90039-3. [DOI] [PubMed] [Google Scholar]
  27. Lønning P. E., Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs. 1988 Jun;35(6):685–710. doi: 10.2165/00003495-198835060-00005. [DOI] [PubMed] [Google Scholar]
  28. Lønning P. E., Kvinnsland S., Thorsen T., Ueland P. M. Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings. Clin Pharmacokinet. 1987 Dec;13(6):393–406. doi: 10.2165/00003088-198713060-00004. [DOI] [PubMed] [Google Scholar]
  29. Lønning P. E., Lien E. A., Lundgren S., Kvinnsland S. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet. 1992 May;22(5):327–358. doi: 10.2165/00003088-199222050-00002. [DOI] [PubMed] [Google Scholar]
  30. Lønning P. E., Skulstad P. Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide. J Steroid Biochem. 1989 Oct;33(4A):565–571. doi: 10.1016/0022-4731(89)90042-3. [DOI] [PubMed] [Google Scholar]
  31. MacNeill F. A., Jones A. L., Jacobs S., Lønning P. E., Powles T. J., Dowsett M. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer. 1992 Oct;66(4):692–697. doi: 10.1038/bjc.1992.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Pasqualini J. R., Gelly C., Nguyen B. L., Vella C. Importance of estrogen sulfates in breast cancer. J Steroid Biochem. 1989;34(1-6):155–163. doi: 10.1016/0022-4731(89)90077-0. [DOI] [PubMed] [Google Scholar]
  33. Reed M. J., Lai L. C., Owen A. M., Singh A., Coldham N. G., Purohit A., Ghilchik M. W., Shaikh N. A., James V. H. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer. Cancer Res. 1990 Jan 1;50(1):193–196. [PubMed] [Google Scholar]
  34. Ruder H. J., Loriaux L., Lipsett M. B. Estrone sulfate: production rate and metabolism in man. J Clin Invest. 1972 Apr;51(4):1020–1033. doi: 10.1172/JCI106862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Santen R. J., Demers L. M., Adlercreutz H., Harvey H., Santner S., Sanders S., Lipton A. Inhibition of aromatase with CGS 16949A in postmenopausal women. J Clin Endocrinol Metab. 1989 Jan;68(1):99–106. doi: 10.1210/jcem-68-1-99. [DOI] [PubMed] [Google Scholar]
  36. Santen R. J., Santner S., Davis B., Veldhuis J., Samojlik E., Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab. 1978 Dec;47(6):1257–1265. doi: 10.1210/jcem-47-6-1257. [DOI] [PubMed] [Google Scholar]
  37. Santner S. J., Leszczynski D., Wright C., Manni A., Feil P. D., Santen R. J. Estrone sulfate: a potential source of estradiol in human breast cancer tissues. Breast Cancer Res Treat. 1986;7(1):35–44. doi: 10.1007/BF01886734. [DOI] [PubMed] [Google Scholar]
  38. Vermeulen A., Paridaens R., Heuson J. C. Effects of aminoglutethimide on adrenal steroid secretion. Clin Endocrinol (Oxf) 1983 Dec;19(6):673–682. doi: 10.1111/j.1365-2265.1983.tb00044.x. [DOI] [PubMed] [Google Scholar]
  39. Williams C. J., Barley V., Blackledge G., Hutcheon A., Kaye S., Smith D., Keen C., Webster D. J., Rowland C., Tyrrell C. Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer. Cancer Treat Rep. 1987 Dec;71(12):1197–1201. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES